No abstract

Easy access to radioiodinated and 211At-labelled bio(macro)molecules is essential to develop new strategies in nuclear imaging and targeted radionuclide therapy of cancers. Yet, the labelling of complex molecules with heavy...

Supporting information for this article is given via a link at the end of the document.

No abstract

No abstract

In this study we investigated vector labeled 225 Ac and unbound 213 Bi, which has the longest half-life of the 225 Ac decay daughters and is known to relocate and accumulate in the kidneys. We compared the pharmacokinetics of in vivo generated 213 Bi and vector labeled 225 Ac for three different vectors in murine cancer models (7.16.4 antibodies against breast cancer; anti-VLA-4 antibodies against melanoma; PSMA-targeted small molecule against castrate resistant prostate cancer). The mice were injected i.v. by the tail vein with the 225 Ac labeled vectors and sacrificed at specific times after administration. The organs and tissues of interest were blood, liver, kidneys and spleen, which were harvested and directly measured in a gamma well counter in 1 minute intervals for up to 5 hours. The measured data was fitted with a bi-exponential function to determine the amount of unbound 213

No abstract